MUHN HANS-PETER
No ORCID on file
· 120 papers in corpus
· active 1998-2012
Frequent coauthors
- FRITZEMEIER KARL-HEINRICH 108
- LEHMANN MANFRED 96
- KRATTENMACHER ROLF 96
- STREHLKE PETER 96
- SCHOELLKOPF KLAUS 96
- HEINRICH NIKOLAUS 96
- PANKNIN OLAF 24
- RING SVEN 12
- THIEME INA 12
- BRAEUER NICO 12
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2012
The disclosure relates to 8beta-substituted estra-1,3,5(10)-triene derivatives of general formula (I), wherein the variables are as defined in the specification, their use as pharmaceutical active ingredients, which have in vitro a higher a…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2011
Pyridinone derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-rel…
2004
The nonsteroid gestagens can be used individually or in combination with estrogens in contraceptive preparations, in the treatment of endometriosis, as well as of gynaecological distrurbances. The compounds can find also application in the …